[Effectiveness of 5-fluorouracil combined with hormones in low dose as a basal treatment for prostatic carcinoma].

In the treatment of prostatic carcinoma, administration of some therapeutic agents, e.g. hormones, continuously as a basal treatment, and other proper treatment, e.g. irradiation or chemotherapy or both, were combined for occasional recurrence of the disease as additional treatment. Effectiveness of 5-fluorouracil in combination with hormones (estrogen or gestagen) in low doses, as a basal treatment, was compared with that of hormones alone in high doses. 5-Fluorouracil at 200 mg/day doses combined with gestagen (allylestrenol or chloromadinone acetate) at 50 mg/day doses was compared with estrogen (hexestrol) at 60 mg/day doses in 30 randomized patients with previously untreated prostatic carcinoma. On the other hand, 5-fluorouracil at 200 mg/day doses combined with hexestrol at 30 mg/day doses was compared with hexestrol at 60 mg/day doses also in 26 randomized patients with carcinoma already well controlled by hexestrol at 60 mg/day doses for more than two years. In patients of the former group treated with 5-fluorouracil and gestagen the rate of recurrence was 20%, mean effective period of therapy was 69 months and 5-year survival rate was 73%, although, in patients treated with high dose estrogen, the rate of recurrence was 60%, mean effective period was 43 months and 5-year survival rate was 55%. At occasional recurrence of the disease, in nearly half the patients in both groups, the disease responded to additional treatments and remission was obtained again. In patients of the latter group with already well controlled disease, no significant difference in prognosis was observed between patients treated with 5-fluorouracil plus low dose estrogen and those treated with high dose estrogen alone.(ABSTRACT TRUNCATED AT 250 WORDS)

The therapeutic effect of concurrent administration of 5-fluorouracil and allylestrenol or hexestrol in small doses on prostatic carcinoma.

A trial to reduce the dosage of estrogen or to substitute it by other agents was done as a treatment of prostatic carcinoma. Either the combination of 5-FU (200 mg/day) and allylestrenol (50 mg/day), or 5-FU and hexestrol (20 mg/day) was given to 24 cases of prostatic carcinoma, 4 of whom were relapsed hormonal-resistant cases, 14 cases were controlled by large doses of estrogen and 6 were newly treated cases. No progressions were observed following 3 months of therapy. In 5 cases, progression was observed after 6 months. Deteriorated cases increased to 6 cases after 12 months. The effective rate, according to the "vital score," which is proposed as a parameter of the physical condition of patients with prostatic carcinoma, was calculated to be 100% at 3 months, 77% at 6 months, and 71% at 12 months.